ncreased Sales 428% Year-over-Year

Signed 5 Year Exclusive Distribution Agreement for Poland

Launched Premium Recreational Brand COVE

Added 70,000 KG of Additional Capacity through Cronos GrowCo JV

Signed 5 Year Take-or-Pay Supply Agreement for 100,000 KG

TORONTOAug. 14, 2018 /CNW/ – Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (Cronos Group” or the “Company“), today announced financial results for the second quarter ended June 30, 2018.

“This year and subsequently, this quarter is about setting the stage and establishing Cronos Group’s strategy for future growth,” said Mike Gorenstein, CEO of Cronos Group. “Cronos Group delivered encouraging results across the Company in the second quarter with sales growing among all of our products and channels, impressive improvements in cultivation yields since the start of the year, and continued business development success in penetrating new markets and establishing new partnerships for expansion.”

“We pushed the business forward while achieving great milestones for the Company and this is only the beginning. Cronos Group is prepared for the domestic recreational market with the launch of our first premium-focused brand COVE™ and is applying a thoughtful approach to our supply and inventory build. Simultaneously, we are working to advance the operations within our current global footprint and bring new partnerships and distribution relationships to the table. We are excited by the progress we are making to execute against our strategy,” concluded Mike Gorenstein.

Second Quarter 2018 Business Highlights

  • Construction of Building 4, Cronos Group’s 286,000 sq. ft. purpose-built indoor production facility located in Stayner, Ontario remains on schedule. Building 4 is ready to commence cultivation upon receipt of the Health Canada license which the Company expects imminently. The state-of-the-art facility is built to GMP standards and has the latest in cutting-edge automation technology.
  • Cronos Australia was granted a medicinal cannabis Manufacture License by the Australian Office of Drug Control in June 2018. This license permits manufacturing of cannabinoid based products in Australia and is required for all forms of extraction, refining, concentration and transformation of the cannabis plant. This license rounds out the licenses for domestic production, which includes the medicinal cannabis cultivation license and research license and brings Cronos Group one step closer to full scale operations in Australia.
  • In June 2018, Cronos entered into a strategic distribution partnership with Delfarma Sp. Zo.o (“Delfarma“). Delfarma is a pharmaceutical wholesaler with a distribution network of over 5,000 pharmacies and more than 200 hospitals that collectively reaches approximately 40% of the Polish domestic market. Under the five-year exclusive distribution agreement, Cronos will supply PEACE NATURALS™ branded cannabis products to Delfarma for distribution within Poland.
  • Cronos Group previewed its premium recreational brand COVE™ at the May 2018 LIFT Conference. COVE™ was born in the Okanagan Valley in British Columbia, which is known for producing some of the world’s finest cannabis. COVE™ products are non-irradiated and hand-trimmed using only the best result of each harvest. By avoiding shortcuts like harsh refining processes, COVE™ is able to maintain the natural balance of the plant across all of the brand’s terpene rich cannabis extracts and brings the highest quality products to its consumers.
  • On May 23, 2018 the trading of Cronos Group’s common shares in Canada were up-listed from the TSX Venture Exchange to the Toronto Stock Exchange (“TSX“). Cronos Group’s common shares are listed under the symbol “CRON” on both the NASDAQ Global Market and the TSX.
  • In May 2018, the board of directors approved the appointment of KPMG LLP as independent auditor of the Company, which was subsequently approved by a majority of votes cast by shareholders at the Company’s Annual and Special Meeting of Shareholders on June 28, 2018.
  • Cronos Group bolstered its board of directors with the appointment of Michael Coates. Mr. Coates was elected to the board of directors by a majority of votes cast by shareholders at the Company’s Annual and Special Meeting of Shareholders. Michael Coates was President and Chief Executive Officer, Americas Region of Hill+Knowlton Strategies (“H+K“), a global public relations and integrated communications agency, from 2014 to 2016 and retired as Global Vice Chairman of H+K in 2017. In June 2018, Michael served as a member of the Premier of Ontario’s transition team.

Business Highlights Subsequent to Second Quarter 2018

  • In July 2018, Cronos Group announced a 50/50 strategic joint venture with a group of investors led by Bert Mucci, a leading Canadian large-scale greenhouse operator. The entity created by this new partnership, Cronos Growing Company Inc. (“Cronos GrowCo“), expects to construct an 850,000 square foot, purpose-built, GMP certified greenhouse for cannabis production on approximately 100 acres of land owned by Cronos GrowCo in Kingsville, Ontario. Once fully operational, the greenhouse is expected to produce up to 70,000 kilograms of cannabis annually.
  • Cronos Group entered into a supply agreement with one of the largest cannabis companies in the world by revenues in the first quarter of 2018, Cura Cannabis Solutions (“Cura“). Cura signed a five year take-or-pay supply agreement to purchase a minimum of 20,000 kilograms of cannabis per annum from Cronos GrowCo starting from the date Cura receives its production and sales licenses from Health Canada. Cura also expects to build its proprietary, state-of-the-art extraction facility on a parcel of land owned by Cronos Group in the heart of Okanagan Valley, British Columbia.

Second Quarter 2018 Financial Results

  • Cronos strengthened liquidity by raising $100.0 million of gross proceeds through a bought deal offering of common shares in April 2018. As of June 30, 2018, total liquidity was $118.0 million, which provides Cronos Group significant runway to execute on its strategic priorities.
  • Second quarter 2018 revenues totaled $3.4 million, as compared to $0.6 million for the second quarter 2017, representing an increase of $2.8 million, or 428%. The main drivers associated with the increase in revenues are an expansion in patient onboarding, an increase in average sales price and the continued strong growth in our cannabis oil offering.
  • Second quarter 2018 cannabis oil sales accounted for 40% of domestic medical sales.
  • Finished goods inventory and biological assets increased by 46% quarter-over-quarter to 2,451 kilograms as the Company focuses on building inventory for the adult-use market.

Conference Call
The Company will host a conference call and live audio webcast on Tuesday, August 14, 2018 at 8:30 a.m. EST to discuss second quarter 2018 results. The call will last approximately one hour. Instructions for the conference call are provided below:

Live Audio Webcasthttps://thecronosgroup.com/investor-relations
Toll-free dial-in number: (888) 231-8191
International dial-in number: (647) 427-7450
Conference ID: 9963107

Additionally, an audio replay of the conference call will be available two hours after the call’s completion and until 11:59 p.m. EST on August 28, 2018. Instructions for the audio replay are provided below:

Toll-free dial-in number: (855) 859-2056
Passcode: 9963107

About Cronos Group
Cronos Group is a globally diversified and vertically integrated cannabis company with a presence across four continents. The Company operates two wholly-owned Canadian licensed producers regulated under Health Canada’s Access to Cannabis for Medical Purposes Regulations: Peace Naturals Project Inc., which was the first non-incumbent medical cannabis license granted by Health Canada, and Original BC Ltd., which is based in the Okanagan Valley, British Columbia. The Company has multiple international production and distribution platforms including in GermanyPolandIsrael and Australia. The Company intends to continue to rapidly expand its global footprint as it focuses on building an international iconic brand portfolio and developing disruptive intellectual property. Cronos Group is committed to building industry leading companies that transform the perception of cannabis and responsibly elevate the consumer experience.

Forward-looking statements
This news release contains “forward-looking information” and “forward-looking statements” within the meaning of applicable securities laws (collectively, “forward-looking statements”). All statements contained herein that are not clearly historical in nature may constitute forward-looking statements. In some cases, forward-looking statements can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy. Forward-looking statements include estimates, plans, expectations, opinions, forecasts, projections, targets, guidance or other statements that are not statements of historical fact. Forward-looking statements are provided for the purposes of assisting the reader in understanding our financial performance, financial position and cash flows as at and for periods ended on certain dates and to present information about management’s current expectations and plans relating to the future and the reader is cautioned that such information may not be appropriate for any other purpose. Some of the forward-looking statements contained in this press release, include, but are not limited to, statements with respect to: our business and operations, our strategy for future growth, growing our global footprint, establishing partnerships and distribution relationships, the expansion of the Company’s growing and production capacities, the construction of our facilities and our intention to build an international iconic brand portfolio and develop disruptive intellectual property. Forward-looking statements are based upon certain material assumptions that were applied in drawing a conclusion or making a forecast or projection, including management’s perceptions of historical trends, current conditions and expected future developments, as well as other considerations that are believed to be appropriate in the circumstances. While we consider these assumptions to be reasonable based on information currently available to management, there is no assurance that such expectations will prove to be correct. By their nature, forward-looking statements are subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking statements in this press release. Such factors include, without limitation, those discussed in the Company’s current MD&A and Annual Information Form, both of which have been filed on SEDAR and can be accessed at www.sedar.com. Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking statements. Forward-looking statements contained herein are made as of the date of this press release and are based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking statements are made. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking statements, except as required by applicable law.

Cronos Group Inc.

Unaudited Condensed Interim Consolidated Statements of Financial Position

As at June 30, 2018 and December 31, 2017

(in thousands of CDN $)

Notes

As at

June 30,

2018

As at

December 31,

2017

Assets

Current assets

Cash

$

89,609

$

9,208

Accounts receivable

22(i)

2,844

1,140

Sales taxes receivable

6,952

3,114

Prepaids and other receivables

4,112

790

Biological assets

6

6,899

3,722

Inventory

6

12,334

8,416

Loan receivable

7,22(i)

314

314

Total current assets

123,064

26,704

Promissory note receivable

8,22(i)

1,304

Investment in Whistler

9

3,851

3,807

Other investments

10

725

1,347

Property, plant and equipment

11

93,657

56,172

Intangible assets

12

11,043

11,207

Goodwill

13

1,792

1,792

Total assets

$

235,436

$

101,029

Liabilities

Current liabilities

Accounts payable and other liabilities

22(ii)

$

2,333

$

7,878

Total current liabilities

2,333

7,878

Construction loan payable

14

5,565

5,367

Deferred income tax liability

21

268

1,416

Total liabilities

8,166

14,661

Shareholders’ equity

Share capital

15(a)

224,742

83,559

Shares to be issued

15(c)

17

Warrants

16(a)

1,868

3,364

Stock options

16(b)

3,810

2,289

Accumulated deficit

(4,051)

(3,724)

Accumulated other comprehensive income

884

880

Total shareholders’ equity

227,270

86,368

Total liabilities and shareholders’ equity

$

235,436

$

101,029

Commitments and contingencies

20

Subsequent events

25

Cronos Group Inc.

Unaudited Condensed Interim Consolidated Statements of Operations and Comprehensive Income (Loss)

For the three and six months ended June 30, 2018 and June 30, 2017

(in thousands of CDN $, except share and per share amounts)

Three Months Ended

June 30,

Six Months Ended

June 30,

Notes

2018

2017

2018

2017

Revenue

17

$

3,394

$

643

$

6,339

$

1,157

Cost of sales

Inventory expensed to cost of sales, before fair value adjustments

5,6

1,254

215

2,821

413

Gross profit before fair value adjustments

2,140

428

3,518

744

Fair value adjustments

Unrealized change in fair value of biological assets

5,6

(6,831)

(1,122)

(9,575)

(2,701)

Realized fair value adjustments on inventory sold in the period

5,6

2,625

429

4,819

1,288

Total fair value adjustments

(4,206)

(693)

(4,756)

(1,413)

Gross profit

6,346

1,121

8,274

2,157

Operating expenses

Sales and marketing

364

87

950

131

General and administrative

4,219

1,872

6,680

3,208

Share-based payments

16(b),19

950

439

1,724

631

Depreciation and amortization

11,12

323

228

608

429

Total operating expenses

5,856

2,626

9,962

4,399

Operating income (loss)

490

(1,505)

(1,688)

(2,242)

Other income (expense)

Interest income (expense)

(37)

13

(59)

(137)

Share of income from Whistler investment

9

3

313

44

416

Gain on other investments

10

1,330

221

1,271

Total other income (expense)

(34)

1,656

206

1,550

Income (loss) before income taxes

456

151

(1,482)

(692)

Income tax recovery

21

(267)

(23)

(1,155)

(22)

Net income (loss)

$

723

$

174

$

(327)

$

(670)

Other comprehensive income

Gain on revaluation and disposal of other investments, net of tax

10,21

39

11

4

694

Comprehensive income (loss)

$

762

$

185

$

(323)

$

24

Net income (loss) per share

Basic and diluted

18

$

0.00

$

0.00

$

(0.00)

$

(0.01)

Weighted average number of outstanding shares

Basic

18

175,529,196

132,647,546

166,343,078

128,824,503

Diluted

18

211,524,230

167,787,028

166,343,078

128,824,503

Cronos Group Inc.

Unaudited Condensed Interim Consolidated Statements of Cash Flows

For the three and six months ended June 30, 2018 and June 30, 2017

(in thousands of CDN $)

Three Months Ended

June 30,

Six Months Ended

June 30,

Notes

2018

2017

2018

2017

Operating activities

Net income (loss)

$

723

$

174

$

(327)

$

(670)

Items not affecting cash:

Unrealized change in fair value of biological assets

5,6

(6,831)

(1,122)

(9,575)

(2,701)

Realized fair value adjustments on inventory sold in the period

5,6

2,625

429

4,819

1,288

Share-based payments

16(b),19

950

439

1,724

631

Depreciation and amortization

11,12

575

228

1,115

429

Share of income from Whistler investment

9

(3)

(313)

(44)

(416)

Gain on other investments

10

(1,330)

(221)

(1,271)

Deferred income tax recovery

21

(267)

(23)

(1,155)

(22)

Foreign exchange loss (gain)

4

(12)

(2,224)

(1,518)

(3,676)

(2,732)

Net changes in non-cash working capital:

Accounts receivable

(318)

(55)

(1,704)

(191)

Sales taxes receivable

(2,686)

(3,838)

Prepaids and other receivables

544

(2,087)

(3,322)

(2,152)

Biological assets

4,422

1,079

6,398

1,711

Inventory

(5,945)

(883)

(8,737)

(2,093)

Accrued interest on loan receivable

(5)

Accounts payable and other liabilities

(659)

136

(5,750)

208

Cash flows used in operating activities

(6,866)

(3,328)

(20,629)

(5,254)

Investing activities

Repayment of purchase price liability

(1,299)

Investment in Whistler

9

(1,076)

(1,076)

Investment in ABcann Global Corporation

10

(1,016)

(1,016)

Proceeds from sale of other investments

10

280

1,683

967

1,771

Payment to exercise ABcann Global Corporation warrants

10

(113)

Advances of promissory note receivable

8

(378)

(1,304)

Purchase of property, plant and equipment

11

(30,025)

(3,494)

(37,667)

(5,529)

Purchase of intangible assets

12

(38)

(169)

Cash flows used in investing activities

(30,161)

(3,903)

(38,286)

(7,149)

Financing activities

Proceeds from exercise of warrants

15(b)

132

245

1,412

889

Proceeds received for shares to be issued

15(c)

961

Proceeds from exercise of options

16(b)

467

185

540

442

Proceeds from share issuance

15(a)

100,032

146,032

17,336

Share issuance costs

(6,363)

(9,444)

(1,322)

Payment of accrued interest on construction loan

14

(185)

Repayment of mortgage payable

(4,000)

(4,000)

Cash flows provided by (used in) financing activities

94,268

(3,570)

139,316

13,345

Net change in cash

57,241

(10,801)

80,401

942

Cash – beginning of period

32,368

15,207

9,208

3,464

Cash – end of period

$

89,609

$

4,406

$

89,609

$

4,406

Supplemental cash flow information

Interest paid

$

189

$

80

$

496

$

200

SOURCE Cronos Group Inc.

For further information: Anna Shlimak, Investor Relations, Tel: (416) 504-0004, investor.relations@thecronosgroup.com

Related Links

thecronosgroup.com